Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo

Blood

Volumn 114, Issue 14, 2009, Pages 3074-3083

  Romay Penabad, Zurina ^a   Montiel Manzano, Maria Guadalupe ^b   Shilagard, Tuya ^c   Papalardo, Elizabeth ^a   Vargas, Gracie ^a,c   Deora, Arun B ^d   Wang, Michael ^a   Jacovina, Andrew T ^d   Garcia Latorre, Ethel ^e   Reyes Maldonado, Elba ^e   Hajjar, Katherine A ^d   Pierangeli, Silvia S ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; IMMUNOGLOBULIN G; LIPOCORTIN 2; MONOCLONAL ANTIBODY; PHOSPHOLIPID ANTIBODY; THROMBOPLASTIN; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLOOD VESSEL INJURY; CELL CULTURE; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANNEXIN A2; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; AORTA; BLOTTING, WESTERN; CARDIOVASCULAR DISEASES; CAROTID ARTERIES; CELLS, CULTURED; E-SELECTIN; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULIN G; INTERCELLULAR ADHESION MOLECULE-1; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; THROMBOPLASTIN; UMBILICAL VEINS; VASCULAR CELL ADHESION MOLECULE-1;

EID: 70449509134     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-11-188698     Document Type: Article

References (59)

1. Harris EN. Syndrome of the black swan. Br J Rheumatol. 1987;26:324-326.
2. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295-306.
3. 2 glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A. 1990;87:4120-4124.
4. Fleck RA, Rapaport SI, Rao LV. Anti-prothrombin antibodies and the lupus anticoagulant. Blood. 1988;72:512-519.
5. Oosting JD, Derksen RH, Bobbink IW, et al. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C or protein S: an explanation for their pathogenic mechanism? Blood. 1993;81:2618-2625.
6. 2 glycoprotein I in the expression of lupus anticoagulant activity. Blood. 1994;83:2878-2892.
7. Marciniak E, Romond EH. Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood. 1989;74:2426-2432. (Pubitemid 19286462)
8. 2 glycoprotein I and induce endothelial activation. Arthritis Rheum. 1997;40:551-561.
9. Meroni PL, Tincani A, Sepp N, et al. Endothelium and the brain in CNS lupus. Lupus. 2003;12:919-928.
10. Di Simone N, Meroni PL, Del Papa N, et al. Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered β2-glycoprotein I. Arthritis Rheum. 2000;43:140-150. (Pubitemid 30368223)
11. 2 glycoprotein-I on trophoblast proliferation as a mechanism for fetal death. Lancet. 1998;352:1037-1038.
12. Pierangeli SS, Colden-Stanfield M, Liu X, et al. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation. 1999;99:1997-2002. (Pubitemid 29183897)
13. 2 glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster. Blood. 2003;101:157-162.
14. Blank M, Cohen J, Toder V, Shoenfeld Y. Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies. Proc Natl Acad Sci U S A. 1991;88:3069-3073. (Pubitemid 21916560)
15. 2 glycoprotein I and the homologous catalytic domains of several serine proteases. Arthritis Rheum. 2007;56:1638-1647.
16. Chen XX, Gu YY, Li SJ, et al. Some plasmin-induced antibodies bind to cardiolipin, display lupus anticoagulant activity and induce fetal loss in mice. J Immunol. 2007;178:5351-5356.
17. Vaarala O, Alfthan G, Jauhiainen M, et al. Cross-reaction between antibodies to oxidized low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet. 1993;341:923-925. (Pubitemid 23109111)
18. 2 glycoprotein I and monoclonal anticardiolipin antibodies on extrinsic fibrinolysis. Semin Thromb Hemost. 2000;26;85-90.
19. Cesarman-Maus G, Rios-Luna NP, Deora AB, et al. Autoantibodies against the fibrinolytic receptor, annexin A2, in antiphospholipid syndrome. Blood. 2006;107:4375-4382. (Pubitemid 43801363)
20. Lisman T, De Groot PG, Meijers JC, Rosendaal FR. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood. 2005;105:1102-1105. (Pubitemid 40170881)
21. Forastiero R, Martinuzzo M. Prothrombotic mechanisms based on the impairment of fibrinolysis in the antiphospholipid syndrome. Lupus. 2008;17:872-877.
22. Hajjar KA, Jacovina AT, Chacko J. An endothelial cell receptor for plasminogen/tissue plasminogen activator: I. Identity with annexin II. J Biol Chem. 1994;269:21191-21197. (Pubitemid 24978790)
23. Kaczan-Bourgois D, Salles JP, Hullin F, et al. Increased content of annexin II (p36) and p11 in human placenta brush-border membrane vesicles during syncytiotrophoblast maturation and differentiation. Placenta. 1996;17:669-676. (Pubitemid 26373744)
24. Ling Q, Jacovina AT, Deora A, et al. Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. J Clin Invest. 2004;113:38-48. (Pubitemid 38541630)
25. Menell JS, Cesarman GM, Jacovina AT, et al. Annexin II and bleeding in acute promyeolocytic leukemia. N Engl J Med. 1999;340:994-1004.
26. Olwill SA, McGlynn H, Gilmore WS, Alexander HD. Annexin II cell surface and mRNA expression in human acute myeloid cell lines. Thromb Res. 2005;115:109-114. (Pubitemid 39572763)
27. Sebastiani P, Ramoni MF, Nolan V, et al. Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia. Nat Genet. 2005;37:435-440. (Pubitemid 40490496)
28. Simantov R, LaSala JM, Lo SK, et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest. 1995;96:2211-2219.
29. Espinola RG, Liu X, Colden-Stanfield M, et al. E-selectin mediates pathogenic effects of antiphospholipid antibodies. J Thromb Haemost. 2003;1:843-848.
30. Pierangeli SS, Espinola RG, Liu X, Harris EN. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circ Res. 2001;88:245-250. (Pubitemid 32147315)
31. Cuadrado MJ, López-Pedrera C, Khamashta MA, et al. Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression. Arthritis Rheum. 1997;40:834-841. (Pubitemid 27199998)
32. Vega-Ostertag M, Casper K, Swerlick R, et al. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum. 2005;52:1545-1554. (Pubitemid 40663946)
33. Forastiero RR, Martinuzzo ME, De Larranaga GF. Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprosy related antiphospholipid antibodies. Lupus. 2005;14:129-136.
34. Williams FM, Parmar K, Hughes GR, Hunt BJ. Systemic endothelial cell markers in primary antiphospholipid syndrome. Thromb Haemost. 2000;84:742-746. (Pubitemid 30946929)
35. 2 glycoprotein I to human endothelial cells is mediated by annexin II. J Biol Chem. 2000;275:15541-15548.
36. 2 glycoprotein I antibodies. Blood. 2005;105:1964-1969.
37. Harris EN. Antiphospholipid antibodies. Br J Haematol. 1990;74:1-9.
38. Palomo I, Pereira J, Alarcón M, et al. Prevalence and isotype distribution of antiphospholipid antibodies in unselected Chilean patients with venous and arterial thrombosis. Clin Rheumatol. 2004;23:129-133. (Pubitemid 38559183)
39. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
40. 2GPI) alone. Lupus. 1998;7:341-346.
41. Deora AB, Kreitzer G, Jacovina AT, Hajjar KA. An annexin 2 phosphorylation switch mediates p11 dependent translocation of annexin 2 to the cell surface. J Biol Chem. 2004;279:43411-43418. (Pubitemid 39390640)
42. He KL, Deora AB, Xiong H, et al. Endothelial cell annexin A2 regulates polyubiquitination and degradation of its binding parter S100A10/p11. J Biol Chem. 2008;283:19192-19200.
43. Vega-Ostertag ME, Ferrara DE, Romay-Penabad Z, et al. Role of p38 mitogen-activated protein kinase in antiphospholipid antibody-mediated thrombosis and endothelial cell activation. J Thromb Haemost. 2007;5:1828-1834. (Pubitemid 47288938)
44. Day SM, Reeve JL, Pedersen B, et al. Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. Blood. 2005;105:192-198. (Pubitemid 40053082)
45. Ferrara DE, Weiss D, Carnell PH, et al. Quantitative 3D fluorescence technique for the analysis of en face preparations of arterial walls using quantum dot nanocrystals and two-photon excitation laser scanning microscopy. Am J Physiol. 2006;290:R114-R123.
46. Jaiswal JK, Simon SM. Potentials and pitfalls of fluorescent quantum dots for biological imaging. Trends Cell Biol. 2004;14:497-504.
47. Gao X, Nie S. Molecular profiling of single cells and tissue specimens with quantum dots. Trends Biotechnol. 2003;21:371-373. (Pubitemid 37025770)
48. Chan WC, Maxwell DJ, Gao X, et al. Luminescent quantum dots for multiplexed biological detection and imaging. Curr Opin Biotechnol. 2002;13:40-46. (Pubitemid 34146546)
49. Chan WC, Nie S. Quantum dot bioconjugates for ultrasensitive nonisotopic detection. Science. 1998;281:2016-2018. (Pubitemid 28475486)
50. Suo J, Ferrara DE, Sorescu D, et al. Hemodynamic shear stresses in mouse aortas: implications for atherogenesis. Arterioscler Thromb Vasc Biol. 2007;27:346-351. (Pubitemid 46143050)
51. 2GPI-induced tissue factor expression on monocytes. Cell Res. 2007;17:737-739.
52. 2 glycoprotein I antibodies induce monocyte release of tumor necrosis factor α and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum. 2007;56:2687-2697.
53. Bu C, Gao L, Xie W, et al. β2 glycoprotein I is a cofactor for tissue plasminogen activator-mediated plasminogen activation. Arthritis Rheum. 2009;60:559-568.
54. Raschi E, Testoni C, Bosisio D, et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood. 2003;101:3495-3500. (Pubitemid 36857933)
55. 2GPI antibodies is mediated by annexin II cross-linking and may involve TLR-4 [abstract]. Blood. 2004;104:83a. Abstract 278.
56. Pierangeli SS, Vega-Ostertag ME, Raschi E, et al. Toll-like receptor and antiphospholipid-mediated thrombosis: in vivo studies. Ann Rheum Dis. 2007;66:1327-1333. (Pubitemid 47492476)
57. 2 glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2′. J Biol Chem. 2003;278:33831-33838.
58. Andersen OM, Benhayon D, Curran T, Willnow TE. Differential binding of ligands to the apolipoprotein E receptor 2′. Biochemistry. 2003;42:9355-9364. (Pubitemid 36959243)
59. 2 glycoprotein I is complement-dependent and requires a priming factor. Blood. 2005;106:2340-2346.